Curing the Cancer Drugs Fund

NHS England has backed NICE's proposed revamp of the U.K. Cancer Drugs Fund, but the Association of the British Pharmaceutical Industry estimates that two-thirds of cancer drugs would be delisted unless the proposed criteria are changed by June.

In addition, gaps that were created in treatment pathways when drugs were delisted over the last two years could remain unfilled for the foreseeable future. That's because when the revamped fund goes into effect July 1, currently covered drugs and newly approved drugs will be reviewed before drugs that were delisted (see "Deprioritizing the Delisted," page 12)...